Recent Achievements and Ongoing Developments at BioSig Technologies

The company BioSig Technologies, a pioneer in digital signal processing and intracardiac signal visualization with its proprietary PURE EPTM System, released an update to shareholders on January 19, 2023, highlighting recent milestones and company developments.

BioSig Tech Increases Patient Case Target

 

Atrial fibrillation causes more than 750,000 hospitalizations in the US each year, resulting in about $6 billion in healthcare spending annually. BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.

The company's first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

BioSig’s non-invasive computerized technology, the PURE EP System, aims to drive procedural efficiency and efficacy in electrophysiology. The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias.

 Recently, BioSig Tech has increased its patient case goal to at least 1,500 procedures by the end of 2021. Previously, the company had announced its target to complete 1,000 patient cases in 2021, having delivered 425 procedures by the end of 2020.

The company said it is currently conducting patient cases in nine medical centers across the country. Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, its first commercial customer, continues to be the biggest user of the technology with over 300 patient cases conducted to date.

Mayo Clinic Florida Campus and the University of Pennsylvania are the second and third largest patient case drivers with 130 and 112 cases, respectively. And more than 800 procedures have been conducted with the PURE EP System in the last 18 months.

BioSig noted that one in 18 Americans suffers from cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the US.

“Patient case volume is one of the leading indications of physician utilization of our technology,” said BioSig CEO Kenneth Londoner in a statement. “We see steady procedural growth in almost all of our centers, which we believe will turn into commercial revenues. This case growth, combined with the consistently positive customer feedback, positions us well to deliver on our target of 20 installation sites by the end of 2021.”

Live Patient Cases to be Supported by BioSig’s PURE EP System During EPLive 2020

BioSig Technologies (NASDAQ: BSGM) is a medical technology company which designs and commercializes an innovative signal processing platform. Bio Sig’s signal processing platform is aimed to uncover the full range of ECG and intra-cardiac signals and to improve signal fidelity.

BioSig Technologies has recently announced that during EPLive 2020, the fifth international symposium on complex arrhythmias, its first product, the PURE EP system, would be featured in several live cases broadcast.

Medical Device Manufacturing

In recent years, the medical device industry has grown steadily, driven by global technological advances, the digitization and incorporation of new technologies, the increasing demand by the population, placing the sector in a complete panorama of growth and development.

Today, different companies manufacture devices capable of measuring the heart rate, pressure, sugar levels and the general state of the patient's health in an easy and affordable way for the population. New information technologies allow real-time diagnostics and automate health measurements, reliably and at the patient's hand at home.

BioSig Resumes Clinical Activities with PURE EP System

Ken Londoner, Chairman and CEO of BioSig Technologies, has recently announced company’s plans to resume its clinical activities with patient cases at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX.

Ken Londoner has also shared that BioSig Technologies is actively negotiating with a number of other centers in order to continue its clinical activities and to initiate new installations of its PURE EP(tm) System.

Ken Londoner: BioSig is a tech platform company

Connecticut company BioSig Tech, began generating revenue from product sales, last November, after winning Food & Drug Administration approval in 2018 to sell its PURE EP system.

The Undiscovered Potential of Bioelectronic Medicine

Bioelectronic Medicine is a new field of medicine that combines neuroscience, molecular biology and bioengineering to delve into the nervous system to treat disease and injury without the use of drugs. Bioelectronic Medicine promises to bring new insights into the diagnosis and treatment of diseases and conditions as varied as cancer, rheumatoid arthritis, inflammatory bowel disease, obesity, diabetes, asthma, paralysis, blindness, bleeding, ischemia, organ transplantation, cardiovascular disease, neurodegenerative diseases, and others.

Bioelectronics is a relatively new branch of healthcare, which, as the name suggests, focuses on the nexus of electronics and biological research. The term can encompass a number of different therapies, but BioSig’s main focus is on creating develop and deliver the advanced signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System. Namely, this Westport-based medical device company is developing a proprietary biomedical signal-processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace.

“Bioelectronic medicine has the potential to transform healthcare throughout the coming decades, much like we’ve seen with the biotech revolution. But the first order of business for those active in the field is to develop a collective vision for how these technologies can improve lives – a vision that other stakeholders can understand and act on,” says Ken Londoner, founder, CEO, and chairman, BioSig Technologies. Since its founding in 2009, BioSig Technologies has been working hard to lead one of the most innovative and most promising frontiers in healthcare. In order to achieve that, BioSig is now ready to commercialize the company’s first product: the PURE EP™ System. Looking further ahead, BioSig expects to publish trial results, grow internationally, and expand their product pipeline.

In 2018, BioSig received FDA 510(k) clearance for PURE EP™, began market launch, and BioSig was uplisted to the NASDAQ national exchange. BioSig Technologies (BSGM) has a market capitalization of $82.52M. Recently BSGM recorded volume of 210046 shares in most recent trading session as compared to an average volume of 185.63K shares. It shows that the shares were traded in the recent trading session and traders shown interest in BSGM stock.